DOI QR코드

DOI QR Code

Treatment of Symptomatic Focal Hepatic Hemangioma with Propranolol in Neonates: Is It Efficient?

  • Jana Lozar Krivec (Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana) ;
  • Nina Lah (Community Health Centre) ;
  • Mojca Glusic (Department of Radiology, University Children's Hospital, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana) ;
  • Orjana Velikonja (Department of Haemato-oncology, University Children's Hospital, University Medical Centre Ljubljana) ;
  • Darja Paro-Panjan (Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana)
  • Received : 2022.05.16
  • Accepted : 2022.11.13
  • Published : 2023.01.15

Abstract

Hepatic hemangiomas (HH) - classified into congenital hepatic hemangiomas (CHH) or infantile hepatic hemangiomas (IHH) - are benign vascular tumors that are mainly asymptomatic, but may cause clinical problems that require treatment. While focal, multifocal, and diffuse IHH are responsive to propranolol treatment, CHH is mainly focal and thought to be resistant to treatment with propranolol. The clinical and imaging distinctions between CHH and IHH in cases of focal lesions can be challenging, while histopathological distinction is mostly lacking in the clinical setting. We report 4 neonatal symptomatic cases of focal HH treated with propranolol, with partial or complete resolution of the tumor, and the positive hemodynamic effect of propranolol in one case. We believe that although clear differentiation cannot be achieved between CHH and IHH without histopathological examination in cases of focal HH in neonates, propranolol treatment should be attempted in symptomatic cases since its benefits outweigh the possible small risk of side effects of propranolol.

Keywords

Acknowledgement

We are grateful to the parents who provided consent to use the data of their children.

References

  1. Iacobas I, Phung TL, Adams DM, Trenor CC 3rd, Blei F, Fishman DS, et al. Guidance document for hepatic hemangioma (infantile and congenital) evaluation and monitoring. J Pediatr 2018;203:294-300.e2.  https://doi.org/10.1016/j.jpeds.2018.08.012
  2. Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al.; ISSVA Board and Scientific Committee. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 2015;136:e203-14.  https://doi.org/10.1542/peds.2014-3673
  3. Gnarra M, Behr G, Kitajewski A, Wu JK, Anupindi SA, Shawber CJ, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr 2016;5:273-80.  https://doi.org/10.5409/wjcp.v5.i3.273
  4. Zavras N, Dimopoulou A, Machairas N, Paspala A, Vaos G. Infantile hepatic hemangioma: current state of the art, controversies, and perspectives. Eur J Pediatr 2020;179:1-8.  https://doi.org/10.1007/s00431-019-03504-7
  5. Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012;47:165-70.  https://doi.org/10.1016/j.jpedsurg.2011.10.037
  6. Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007;42:62-7; discussion 67-8.  https://doi.org/10.1016/j.jpedsurg.2006.09.041
  7. Liang MG, Frieden IJ. Infantile and congenital hemangiomas. Semin Pediatr Surg 2014;23:162-7.  https://doi.org/10.1053/j.sempedsurg.2014.06.017
  8. Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol--a case series. Pediatr Dermatol 2011;28:39-45.  https://doi.org/10.1111/j.1525-1470.2010.01355.x
  9. Sarialioglu F, Yazici N, Erbay A, Boyvat F, Demir S, Ozcay F, et al. A new perspective for infantile hepatic hemangioma in the age of propranolol: experience at Baskent University. Exp Clin Transplant 2017;15(Suppl 2):74-8. 
  10. Ernst L, Grabhorn E, Brinkert F, Reinshagen K, Konigs I, Trah J. Infantile hepatic hemangioma: avoiding unnecessary invasive procedures. Pediatr Gastroenterol Hepatol Nutr 2020;23:72-8.  https://doi.org/10.5223/pghn.2020.23.1.72
  11. Florian-Tutaya LS, Cuba-Valencia L, Bustamante-Encinas SF, Vela-Alfaro FM. Successful use of propranolol in a symptomatic giant congenital hepatic hemangioma. J Neonatol 2020;34:99-102.  https://doi.org/10.1177/0973217920928645
  12. Kawahara Y, Nijima H, Suzuki Y, Furukawa R, Morimoto A. Successful use of propranolol for congenital hepatic hemangioma with Kasabach-Merritt phenomenon. Pediatr Int 2017;59:634-6.  https://doi.org/10.1111/ped.13244
  13. Docx MKF, Vandenberghe P, De Broek V, Govaert P. Propranolol therapy for an abdominal giant haemangioma in a neonate. J Nepal Paediatr Soc 2015;35:189-91. https://doi.org/10.3126/jnps.v35i2.13877
  14. Baena-Gomez MA, Priego Ruiz MP, Mateos Gonzalez E, Pena Rosa MJ, Munoz Sanchez R. [Hepatic hemangiomas: spectacular response to treatment with propranolol]. An Pediatr (Barc) 2015;83:435-7. Spanish.  https://doi.org/10.1016/j.anpedi.2015.05.008
  15. Tsai MC, Liu HC, Yeung CY. Efficacy of infantile hepatic hemangioma with propranolol treatment: a case report. Medicine (Baltimore) 2019;98:e14078. 
  16. Lekwuttikarn R, Josephs S, Teng JM. Successful medical management of life-threatening hepatic hemangioma in neonates. Pediatrics 2019;144:e20191339. 
  17. Lewis D, Hachey K, Fitzgerald S, Vaidya R. Rapidly involuting congenital haemangioma of the liver. BMJ Case Rep 2018;2018:bcr2018224337. 
  18. Koh SP, Leadbitter P, Smithers F, Tan ST. β-blocker therapy for infantile hemangioma. Expert Rev Clin Pharmacol 2020;13:899-915.   https://doi.org/10.1080/17512433.2020.1788938